An anti-ROR1/CD3/HSA tri-specific antibody (biologic T-cell engager) that binds ROR1 on tumor cells and CD3 on T cells to activate cytotoxic T-cell killing of ROR1-positive cancers; the anti-HSA arm binds human serum albumin to extend half-life via FcRn recycling.
Tri‑specific antibody that binds ROR1 on tumor cells and CD3 on T cells to form an immune synapse and activate cytotoxic T‑cell killing of ROR1‑positive cancers; the anti‑HSA arm binds human serum albumin to extend half‑life via FcRn recycling.
YES
DIRECT
Tri-specific T‑cell engager binds ROR1 on tumor cells and CD3 on T cells, forming an immune synapse that activates CTLs to kill ROR1+ cells via perforin/granzyme-mediated apoptosis; HSA binding only extends half-life.
An anti-ROR1/CD3/HSA tri-specific antibody (biologic T-cell engager) that binds ROR1 on tumor cells and CD3 on T cells to activate cytotoxic T-cell killing of ROR1-positive cancers; the anti-HSA arm binds human serum albumin to extend half-life via FcRn recycling.
Tri‑specific antibody that binds ROR1 on tumor cells and CD3 on T cells to form an immune synapse and activate cytotoxic T‑cell killing of ROR1‑positive cancers; the anti‑HSA arm binds human serum albumin to extend half‑life via FcRn recycling.
NO
INDIRECT
CD3+ T cells are not killed; the drug bridges CD3 on T cells to ROR1 on tumor cells, activating T-cell cytotoxicity (perforin/granzyme) against ROR1+ cells.
Rabbit polyclonal anti-thymocyte globulin that depletes T cells to prevent rejection and GVHD.
Rabbit polyclonal anti-thymocyte IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, producing immunosuppression to prevent rejection and GVHD.
YES
DIRECT
Polyclonal anti-thymocyte IgG binds CD45 on leukocytes, activating complement (CDC) and Fc-mediated ADCC, and can induce apoptosis via crosslinking, leading to target-cell depletion.
An anti-ROR1/CD3/HSA tri-specific antibody (biologic T-cell engager) that binds ROR1 on tumor cells and CD3 on T cells to activate cytotoxic T-cell killing of ROR1-positive cancers; the anti-HSA arm binds human serum albumin to extend half-life via FcRn recycling.
Tri‑specific antibody that binds ROR1 on tumor cells and CD3 on T cells to form an immune synapse and activate cytotoxic T‑cell killing of ROR1‑positive cancers; the anti‑HSA arm binds human serum albumin to extend half‑life via FcRn recycling.
NO
INDIRECT
T cells are redirected via CD3 to kill ROR1-positive tumor cells. The anti-HSA arm binds soluble human serum albumin to extend half-life and does not mediate killing of HSA-expressing cells.
Small-molecule BH3-mimetic BCL-2 inhibitor that restores intrinsic mitochondrial apoptosis in CLL cells.
Selective oral BH3-mimetic that inhibits the anti-apoptotic protein BCL-2 by binding its hydrophobic groove, displacing BH3-only proteins (e.g., BIM) and enabling BAX/BAK-mediated mitochondrial outer membrane permeabilization, thereby restoring intrinsic apoptosis in BCL-2–dependent tumor cells such as CLL.
YES
DIRECT
Venetoclax directly inhibits BCL-2 (BH3 mimetic), releasing pro-apoptotic BH3-only proteins to activate BAX/BAK, leading to mitochondrial outer membrane permeabilization, caspase activation, and apoptosis in BCL-2–dependent cells.